The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out.

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Available webcasts will be accessible on Skye's website .

"This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including lower risks of endometrial, ovarian, and meningioma cancers, among patients ...

In an effort to address the state’s obesity epidemic and subsequently address the health effects associated with it, the Mississippi Legislature is considering allowing GLP-1 medications such as ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...

FOR millions around the world, fat jabs like Mounjaro and Wegovy have been a godsend for a simple and stress-free way to shed ...

Feeding rats edible microbeads designed to absorb fat helps them lose weight. One day the beads could be used in human foods and drinks to prevent or treat obesity in people.